FDA Generic Drug Review Boosts US Drug Manufacturing

Original Article by Siddhi Mahatole | Reuters | 5 October 2025

The US Food and Drug Administration (FDA) has announced the launch of a new pilot programme. This programme aims to accelerate the review process for generic drugs. Companies research, develop, and manufacture these drugs entirely within the United States. The initiative aims to incentivise pharmaceutical companies to onshore their operations. It strengthens the domestic supply…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
More Articles

Dis-Chem Insurance Branding Non-Compliant says CMS

Dis-Chem health insurance branding issues raise enforcement risk for Centriq’s MyHealth products and potential disruption for policyholders.

National Health Insurance Negotiations: SAMA Seeks NHI Talks

National Health Insurance Negotiations: SAMA meets Motsoaledi after Godongwana urges NHI litigants to seek a settlement.

NHI Truce Talks: Godongwana Pushes Settlement On NHI

NHI truce talks could end court battles and shift focus to workable reforms for universal health coverage.